FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W8002078> ?p ?o ?g. }

• W8002078 endingPage "7" @default.
• W8002078 startingPage "34" @default.
• W8002078 abstract "Irinotecan (Camptosar) is an active chemotherapeutic agent for lung, gastric, esophageal, and colorectal cancers and a potent radiosensitizer. This phase I study was designed to assess the maximum tolerated dose of weekly irinotecan combined with concurrent radiotherapy for patients with locally advanced, unresectable gastric, gastroesophageal junction, or esophageal cancer. Patients who received previous chemotherapy (excluding irinotecan) or who experienced recurrent cancer after surgery were eligible for this protocol. The total dose of radiation did not exceed 50.4 Gy (28 fractions of 1.8 Gy each). The starting dose level of irinotecan was 30 mg/m2 infused over 90 minutes given weekly for 5 weeks. Subsequent dose levels were increased in 10 mg/m2 increments to 40, 50, 60, and 70 mg/m2. Of 15 patients who have been enrolled to date, all are evaluable for toxicities and 12 for response. Major hematologic toxicities (grade 3/4) were neutropenia, chills, hemorrhage, and anemia. Grade 3/4 gastrointestinal toxicities included nausea, vomiting, dehydration, anorexia, and constipation. Other severe nonhematologic toxicities included fatigue, hypotension, and hypothermia, as well as cardiovascular toxicities. There was no severe diarrhea and no treatment-related deaths. Of the 12 evaluable patients, 7 (58%) responded, including 2 complete responses; 4 (30%) had no change and 1 had progressive disease. Survival ranged from 1 month to 15 months, with a median survival of 8 months. When the total dose of irinotecan given concurrently with radiotherapy was higher than 250 mg/m2, patients experienced significantly more severe grade 3/4 toxicities than with lower doses (P = .04), with no improvement in response rate. It was concluded that weekly doses of irinotecan of up to 60 mg/m2 with concurrent radiotherapy given over 5 weeks was feasible and demonstrated good response. This regimen did not cause severe diarrhea or pneumonitis, but neutropenia and fatigue were major toxicities. The study continues to accrue." @default.
• W8002078 created "2016-06-24" @default.
• W8002078 creator A5006430883 @default.
• W8002078 creator A5011760336 @default.
• W8002078 creator A5018129018 @default.
• W8002078 creator A5030797960 @default.
• W8002078 creator A5035147242 @default.
• W8002078 creator A5035766861 @default.
• W8002078 creator A5039388722 @default.
• W8002078 creator A5044064524 @default.
• W8002078 creator A5051520990 @default.
• W8002078 creator A5055398866 @default.
• W8002078 creator A5066197112 @default.
• W8002078 creator A5082224406 @default.
• W8002078 date "2000-12-01" @default.
• W8002078 modified "2023-09-27" @default.
• W8002078 title "Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors." @default.
• W8002078 cites W1536538430 @default.
• W8002078 cites W1567663060 @default.
• W8002078 cites W1755629647 @default.
• W8002078 cites W1896772377 @default.
• W8002078 cites W1903533038 @default.
• W8002078 cites W1952371628 @default.
• W8002078 cites W1982075384 @default.
• W8002078 cites W2001096578 @default.
• W8002078 cites W2016722642 @default.
• W8002078 cites W2018185888 @default.
• W8002078 cites W2020931366 @default.
• W8002078 cites W2067132634 @default.
• W8002078 cites W2094864265 @default.
• W8002078 cites W2095256813 @default.
• W8002078 cites W2128340087 @default.
• W8002078 cites W2160174995 @default.
• W8002078 cites W2166241963 @default.
• W8002078 cites W2169186295 @default.
• W8002078 cites W2246769930 @default.
• W8002078 cites W2397376517 @default.
• W8002078 cites W2409646217 @default.
• W8002078 cites W2413694431 @default.
• W8002078 cites W2419655738 @default.
• W8002078 cites W2429945373 @default.
• W8002078 cites W37120966 @default.
• W8002078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11200147" @default.
• W8002078 hasPublicationYear "2000" @default.
• W8002078 type Work @default.
• W8002078 sameAs 8002078 @default.
• W8002078 citedByCount "7" @default.
• W8002078 countsByYear W80020782016 @default.
• W8002078 countsByYear W80020782020 @default.
• W8002078 crossrefType "journal-article" @default.
• W8002078 hasAuthorship W8002078A5006430883 @default.
• W8002078 hasAuthorship W8002078A5011760336 @default.
• W8002078 hasAuthorship W8002078A5018129018 @default.
• W8002078 hasAuthorship W8002078A5030797960 @default.
• W8002078 hasAuthorship W8002078A5035147242 @default.
• W8002078 hasAuthorship W8002078A5035766861 @default.
• W8002078 hasAuthorship W8002078A5039388722 @default.
• W8002078 hasAuthorship W8002078A5044064524 @default.
• W8002078 hasAuthorship W8002078A5051520990 @default.
• W8002078 hasAuthorship W8002078A5055398866 @default.
• W8002078 hasAuthorship W8002078A5066197112 @default.
• W8002078 hasAuthorship W8002078A5082224406 @default.
• W8002078 hasConcept C121608353 @default.
• W8002078 hasConcept C126322002 @default.
• W8002078 hasConcept C141071460 @default.
• W8002078 hasConcept C2776694085 @default.
• W8002078 hasConcept C2777063308 @default.
• W8002078 hasConcept C2779742542 @default.
• W8002078 hasConcept C2780259306 @default.
• W8002078 hasConcept C2780580376 @default.
• W8002078 hasConcept C2780852908 @default.
• W8002078 hasConcept C509974204 @default.
• W8002078 hasConcept C526805850 @default.
• W8002078 hasConcept C71924100 @default.
• W8002078 hasConcept C90924648 @default.
• W8002078 hasConceptScore W8002078C121608353 @default.
• W8002078 hasConceptScore W8002078C126322002 @default.
• W8002078 hasConceptScore W8002078C141071460 @default.
• W8002078 hasConceptScore W8002078C2776694085 @default.
• W8002078 hasConceptScore W8002078C2777063308 @default.
• W8002078 hasConceptScore W8002078C2779742542 @default.
• W8002078 hasConceptScore W8002078C2780259306 @default.
• W8002078 hasConceptScore W8002078C2780580376 @default.
• W8002078 hasConceptScore W8002078C2780852908 @default.
• W8002078 hasConceptScore W8002078C509974204 @default.
• W8002078 hasConceptScore W8002078C526805850 @default.
• W8002078 hasConceptScore W8002078C71924100 @default.
• W8002078 hasConceptScore W8002078C90924648 @default.
• W8002078 hasIssue "12 Suppl 14" @default.
• W8002078 hasLocation W80020781 @default.
• W8002078 hasOpenAccess W8002078 @default.
• W8002078 hasPrimaryLocation W80020781 @default.
• W8002078 hasRelatedWork W1971329870 @default.
• W8002078 hasRelatedWork W2353188344 @default.
• W8002078 hasRelatedWork W2356972755 @default.
• W8002078 hasRelatedWork W2374862613 @default.
• W8002078 hasRelatedWork W2386923354 @default.
• W8002078 hasRelatedWork W2389892302 @default.

• next